Sure, Eli Lilly’s Tirzepatide-based drugs have caught up significantly to Novo Nordisk’s semaglutide-based ones. As a result, ...
"UK regulators seize illegal weight loss drugs amid global pricing shake-up" was originally created and published by ...
Zacks Investment Research on MSN
NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now?
Novo Nordisk NVO and Structure Therapeutics GPCR have emerged as noteworthy companies in the obesity space. A market leader ...
A boardroom shake-up at Novo Nordisk has handed unprecedented power to its top shareholder, the Novo Nordisk Foundation, ...
A major boardroom shake-up at Novo Nordisk has given the Novo Nordisk Foundation an unprecedented level of control, raising ...
Another week, another twist in the turnaround efforts at Novo Nordisk, the maker of the blockbuster Ozempic and Wegovy weight ...
Dive deeper with STAT+. Gain unlimited access to expert analysis, newsletters, events, and news alerts.
Shares of Eli Lilly and Novo Nordisk fell Friday, Oct. 17 after Pres. Donald Trump said the price of the weight-loss drug Ozempic could soon drop to $150 a month.
Novo Nordisk (NVO) recruits top healthcare analyst Michael Novod, a long time bull of the company, as head of its investor ...
Novo Nordisk A/S found a new leader for its investor relations department in an equity analyst who has recommended buying ...
Trisha Durant has joined Alvotech as SVP of global business development and commercial operation, ex-North America. Harshika ...
Karen Finerman, CEO & Co-founder, Metropolitan Capital Advisors, said in a recent program on CNBC that she likes NVO amid the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback